Protara Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Protara Therapeutics, Inc. (TARA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $12.97 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2025-03-05
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $2.38.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $12.97, a 18.63% decline from fiscal 2023.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $15.94.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2019 was $260.40, a 1857.89% increase from fiscal 2018.
- Protara Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2018 was $13.30, a 411.54% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $12.97 10-K · filed 2025-03-05 | |||
| 2023-12-31 | $15.94 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $14.39 10-Q · filed 2023-11-03 | |||
| 2019-12-31 | $260.40 10-K · filed 2020-03-20 | |||
| 2019-09-30 | $6.51 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $5.14 10-Q · filed 2019-08-07 | |||
| 2018-12-31 | $13.30 10-K · filed 2019-03-13 | |||
| 2018-09-30 | $13.30 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $13.30 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $2.38 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $2.60 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |